Repare Therapeutics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steve Forte
- Full Time Employees
- 129
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7210 Frederick-Banting Montreal QC Canada H4S 2A1
- IPO Date
- Jun 19, 2020
- CIK
- 0001808158
- Website
- reparerx.com
- Similar Companies
- Business
- Repare Therapeutics Inc. (Nasdaq: RPTX) develops synthetic lethality-based precision oncology therapeutics targeting genomic instability and DNA damage repair pathways using its proprietary genome-wide CRISPR-enabled SNIPRx platform; its clinical-stage pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 trials, camonsertib (RP-3500), an ATR inhibitor in Phase 1/2 trials, RP-1664, a Phase 1 PLK4 inhibitor, and RP-3467, a Phase 1 Polo-like theta (Polθ) ATPase inhibitor, alongside undisclosed preclinical programs. The company, founded in 2016 and headquartered in Montreal, Quebec, Canada, with additional operations in Cambridge, Massachusetts, USA, focuses on cancers with high unmet needs through systematic discovery and validation of tumor vulnerabilities. In January 2025, Repare announced a portfolio reprioritization to focus resources on RP-1664 and RP-3467, with initial clinical readouts expected in Q3 2025, while exploring partnerships for lunresertib plus camonsertib (Lunre+Camo) and other assets to extend its cash runway into mid-2027; in May 2025, it out-licensed early-stage discovery platforms and certain intellectual property to DCx Biotherapeutics; and in November 2025, it entered a definitive agreement to be acquired by XenoTherapeutics Inc., with support and voting agreements from significant shareholders, expecting closure in Q1 2026 subject to approvals, after which Repare will become privately held and delist from Nasdaq.
Repare Therapeutics (NASDAQ:RPTX) Trading Up 0.8% – What’s Next?
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% – Here’s Why
Repare Therapeutics Target of Unusually Large Options Trading (NASDAQ:RPTX)
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Repare Therapeutics Inc. (Nasdaq – RPTX), Axalta Coating Systems Ltd. (NYSE – AXTA), Blue Foundry Bancorp (Nasdaq – BLFY), Golden Entertainment, Inc (Nasdaq - GDEN)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—RPTX, CNBN, KMB, and KVUE
Halper Sadeh LLC Encourages THS, RPTX, AXTA Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages RPTX, THS, RMBI Shareholders to Contact the Firm to Discuss Their Rights
Repare Therapeutics Inc. (NASDAQ:RPTX) Receives $3.50 Average PT from Brokerages
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)
Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value
RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders
Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Repare Therapeutics Inc. (RPTX) Reports Break-Even Earnings for Q3
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics